Published in Food and Drug Law Weekly, May 27th, 2005
Approved on March 21, 2005, by the U. S. Food and Drug Administration (FDA), AcrySof ReSTOR is the first and only IOL that uses apodized diffractive technology to provide cataract patients with and without presbyopia a quality range of vision.
In clinical trials, 80% of patients reported "never" wearing reading glasses or bifocals following bilateral cataract surgery. The vast majority of patients who undergo...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.